Prior-Hsct Donor-Derived Cd7 Car T-Cell
T-Cell And NK-Cell Neoplasm
Explore 17 assets in T-Cell And NK-Cell Neoplasm →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Beijing GoBroad Hospital
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06316427CT.gov Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell And NK-Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prior-Hsct Donor-Derived Cd7 Car T-Cell (this asset) | Beijing GoBroad Hospital | P1/2 | CC · 47 |
| Cyclophosphamide | New York Medical College | P3 | BBB |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Cyclosporin A | Medical College of Wisconsin | P3 | B |
| Equine Atg | Masonic Cancer Center, University of Minnesota | P2 | B |
| Umbilical Cord Blood Mononuclear Cells | Masonic Cancer Center, University of Minnesota | P2 | B |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | B |
| Dexasone | National Cancer Institute (NCI) | P1 | CCC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CCC |
+18 more in the T-Cell And NK-Cell Neoplasm cohort
Other indications for Prior-Hsct Donor-Derived Cd7 Car T-Cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Acute Lymphoblastic Leukemia | — | P1/2 | CC · 45 |
| Acute Lymphoblastic Leukemia | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prior-Hsct Donor-Derived Cd7 Car T-Cell in T-Cell And NK-Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prior-hsct-donor-derived-cd7-car-t-cell-t-cell-and-nk-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →